FUJIFILM Healthcare Americas Corporation IVD addresses healthcare needs of patients, prescribers and researcher’s by providing testing that aids in early detection, monitoring for chronic diseases and treatment response. FUJIFILM Healthcare solutions address clinicians, researchers and commercial partners by providing OEM and branded products. Encompassing over 90 years of experience, Fujifilm provides quality manufacturing of in vitro diagnostic products delivering reliable results.
The American Cancer Society estimates that there will be over 40,000 new cases diagnosed and over 30,000 deaths due to liver cancer and intrahepatic bile duct cancer in the United States in 2019*. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and is a leading cause of cancer-related death worldwide**.
Advances in biomarker research have made it possible to assess the risk for the development of hepatocellular carcinoma (HCC) in patients with chronic liver disease.
Discovering biomarkers that can help improve patient care is a primary goal of Fujifilm. Biomarkers may contribute to the assessment of an individual’s state of health, disease progression, and the response to a particular treatment plan.
Fujifilm is leading the way in generating biomarkers tests associated with various disease types, with a focus on chronic liver disease.
The AFP-L3 (lectin-reactive alphafetoprotein) and DCP (des-gammacarboxy prothrombin) tests are intended to be used as an aid in the risk assessment of patients with chronic liver disease for development of HCC in conjunction with other laboratory findings, imaging studies and clinical assessment. The use of AFP-L3 and DCP tests can aid in the early identification of patients with risk of developing HCC.
Fujifilm also offers in vitro diagnostic reagents and systems that provide users with solutions to address further clinical and research needs. With more than 80 years of experience, Fujifilm provides reagents that deliver results across an area of expertise that includes Non-Esterified Fatty Acid (NEFA) used in the diagnosis of various disorders of lipid metabolism, Total Complement Activity (CH50) used to diagnose abnormalities of complement activities such as lupus and rheumatoid arthritis, HDL Cholesterol and LDL Cholesterol (direct) used to assess the risk of developing coronary heart disease, and Urinary Albumin (microalbumin) used for the early detection of diabetes.
FUJIFILM Wako is a leading manufacturer of the highest quality chemistry reagents worldwide. FUJIFILM Wako’s products are the result of over 90 years of dedication to the field of laboratory science and research development. FUJIFILM Wako’s superior research reagents are easy to use and have a robust history of utilization in academia.